Serum heart type fatty acid binding protein levels in metabolic syndrome

• Published in: Endocrine Vol. 36; no. 3; pp. 433 - 437
• Main Authors: Akbal, Erdem, Özbek, Mustafa, Güneş, Fahri, Akyürek, Ömer, Üreten, Kemal, Delibaşı, Tuncay
• Format: Journal Article
• Language: English
• Published: Boston Springer US 01-12-2009
• Subjects: Adult; Biomarkers - analysis; Biomarkers - blood; Cardiovascular Diseases - blood; Cardiovascular Diseases - epidemiology; Cardiovascular Diseases - etiology; Case-Control Studies; Diabetes; Diabetes Complications - blood; Diabetes Complications - epidemiology; Endocrinology; Fatty Acid Binding Protein 3; Fatty Acid-Binding Proteins - analysis; Fatty Acid-Binding Proteins - blood; Female; Humanities and Social Sciences; Humans; Hypertension - blood; Hypertension - complications; Hypertension - epidemiology; Internal Medicine; Male; Medicine; Medicine & Public Health; Metabolic Syndrome - blood; Metabolic Syndrome - complications; Metabolic Syndrome - epidemiology; Middle Aged; multidisciplinary; Original Article; Science; Metabolic syndrome; Diabetes mellitus; Heart fatty acid binding protein
• ISSN: 1355-008X; 1559-0100
• DOI: 10.1007/s12020-009-9243-6

Heart type fatty acid binding protein (H-FABP) is a major cytoplasmic low-molecular weight protein and released into the circulation when the myocardium is injured. Previous studies have demonstrated that H-FABP is closely associated with acute coronary syndrome, hypertrophic and dilated cardiomyopathy, heart failure, stroke, obstructive sleep apnea syndrome, pulmonary embolism. The aim of this study was to investigate serum H-FABP value in the patients with metabolic syndrome (MetS). We measured serum H-FABP levels in 55 consecutive patients with MetS, and 73 age-matched control subjects by using a sandwich enzyme-linked immunosorbent assay. Serum H-FABP levels were significantly higher in patients with MetS than in control subjects 18.37 ± 13.0 and 7.9 ± 6.5 ng/ml, respectively, (
P
 < 0.001). Serum H-FABP levels were significantly higher in patients with diabetic MetS than in without diabetic MetS, 24.0 ± 10.2 and 13.9 ± 12.6 ng/ml, respectively, (
P
: 0,003). There were statistically significant differences between patients without diabetic MetS and control subjects, 13.8 ± 12.6 and 7.9 ± 6.5 ng/ml, respectively, (
P
 = 0.023). Patients with MetS have an increased risk of death from cardiovascular diseases. H-FABP seems to be a marker that will enable the detection of cardiac injury in the early asymptomatic period in patients with MetS.